Our Pipeline

Enabled by our proprietary drug discovery platform, we have developed a diverse pipeline of wholly-owned drug candidates.

Pipeline graphic is not for promotional use.

To learn more about Ono Pharma’s pipeline, click here.

Download Our Pipeline
Research IND-Enabling Phase 1 Phase 2 Phase 3 Regulatory
Submission		 Approved

Tirabrutinibᶜ

Phase 3
BTK Inhibitor

Primary central nervous system lymphoma

Sapablursenᵈ

Phase 2
TMPRSS6 ASO
  • Polycythemia Vera (Phlebotomy Dependent)
  • Phase 2

ONO-4578

Phase 2
EP4 antagonist
  • Colorectal Cancer + nivolumab
  • Phase 2

ONO-2808

Phase 2
S1P5 receptor agonist
  • Multiple System Atrophy

ONO-2020

Phase 2
Epigenetic regulator

ONO-4685

Phase 1
PD-1 x CD3 bispecific antibody

a Prior treatment with 3 or more kinase inhibitors, including imatinib.  
b TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity.  
c Tirabrutinib is under license agreement with ONO PHARMA to Deciphera Pharmaceuticals, LLC.  
d Sapablursen is under license agreement from Ionis Pharmaceuticals to ONO PHARMA and its affiliates.  
1L, first line; 2L, second line; ASO, antisense oligonucleotide; BTK, Bruton tyrosine kinase; CD3, cluster of differentiation 3; cGVHD, chronic graft-versus-host disease; CRPC, castration-resistant prostate cancer; CSF1R, colony-stimulating factor 1 receptor; EP4, prostaglandin E receptor 4; GCN2, general control nonderepressible 2; GIST, gastrointestinal stromal tumor; KIT, receptor tyrosine kinase type III; PD-1, programmed cell death protein 1; PDGFRA, platelet-derived growth factor receptor alpha; RCC, renal cell carcinoma; R/R, relapsing or refractory; S1P5, sphingosine-1- phosphate receptor 5; TGCT, tenosynovial giant cell tumor; TKI, tyrosine kinase inhibitor; TMPRSS6, transmembrane protease serine 6; ULK, Unc- 51–like autophagy activating kinase.